| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2024 | QUELLTX INC | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44MH122052 | Functional drug fingerprinting with all-optical electrophysiology | 000 | 5 | NIH | 10/23/2024 | $0 |
| | 2025 | 2023 | QUIVER BIOSCIENCE INC. | 150 CAMBRIDGEPARK DRIVE 5TH FLOOR | CAMBRIDGE | MA | 02140 | MIDDLESEX | USA | R44MH121169 | A phenotypic screen for compounds that differentially affect excitatory and inhibitory neuronal signaling | 000 | 3 | NIH | 3/25/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $2,779,162 ) |
| | 2024 | 2024 | QUELLTX INC | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44MH135521 | BRITE-Eye: An integrated discovery engine for CNS therapeutic targets driven by high throughput genetic screens, functional readouts in human neurons, and machine learning | 001 | 2 | NIH | 8/1/2024 | $1,278,054 |
| | 2024 | 2024 | QUELLTX INC | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44MH122052 | Functional drug fingerprinting with all-optical electrophysiology | 004 | 5 | NIH | 7/29/2024 | $378,127 |
| | 2024 | 2023 | QUELLTX INC | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44MH122052 | Functional drug fingerprinting with all-optical electrophysiology | 003 | 4 | NIH | 1/23/2024 | $0 |
| | 2024 | 2023 | QUELLTX INC | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44MH135521 | BRITE-Eye: An integrated discovery engine for CNS therapeutic targets driven by high throughput genetic screens, functional readouts in human neurons, and machine learning | 000 | 1 | NIH | 6/6/2024 | $0 |
| | 2024 | 2023 | QUELLTX INC | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44MH121169 | A phenotypic screen for compounds that differentially affect excitatory and inhibitory neuronal signaling | 004 | 3 | NIH | 8/1/2024 | $0 |
| | 2024 | 2023 | QUELLTX INC | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44MH122052 | Functional drug fingerprinting with all-optical electrophysiology | 002 | 4 | NIH | 11/28/2023 | $718,700 |
| | 2024 | 2023 | QUELLTX INC | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44MH121169 | A phenotypic screen for compounds that differentially affect excitatory and inhibitory neuronal signaling | 002 | 3 | NIH | 1/8/2024 | $404,281 |
| | 2024 | 2023 | QUELLTX INC | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44MH121169 | A phenotypic screen for compounds that differentially affect excitatory and inhibitory neuronal signaling | 003 | 3 | NIH | 2/16/2024 | $0 |
| | 2024 | 2022 | QUELLTX INC | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44CA247110 | Development of anti-sense oligonucleotides as a therapeutic for cancer pain through selective block of sodium channel pain targets | 000 | 3 | NIH | 12/21/2023 | $0 |
| | 2024 | 2022 | QUELLTX INC | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44CA247110 | Development of anti-sense oligonucleotides as a therapeutic for cancer pain through selective block of sodium channel pain targets | 001 | 3 | NIH | 7/24/2024 | $0 |
| | 2024 | 2021 | QUELLTX INC | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44AR074820 | A phenotypic screen for osteoarthritic pain therapeutics using all-optical electrophysiology. | 000 | 3 | NIH | 7/15/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $4,379,263 ) |
| | 2023 | 2023 | QUELLTX INC | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44MH122052 | Functional drug fingerprinting with all-optical electrophysiology | 000 | 4 | NIH | 7/1/2023 | $793,383 |
| | 2023 | 2023 | QUELLTX INC | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44MH135521 | BRITE-Eye: An integrated discovery engine for CNS therapeutic targets driven by high throughput genetic screens, functional readouts in human neurons, and machine learning | 000 | 1 | NIH | 9/19/2023 | $1,721,943 |
| | 2023 | 2023 | QUELLTX INC | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44MH121169 | A phenotypic screen for compounds that differentially affect excitatory and inhibitory neuronal signaling | 003 | 3 | NIH | 7/27/2023 | $635,498 |
| | 2023 | 2022 | QUELLTX INC | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44NS125689 | Ultra-high-throughput plate reader for drug discovery using all-optical electrophysiology | 001 | 5 | NIH | 9/8/2023 | $1,228,439 |
| | 2023 | 2021 | QUELLTX INC | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44AR074820 | A phenotypic screen for osteoarthritic pain therapeutics using all-optical electrophysiology. | 000 | 3 | NIH | 5/17/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $995,305 ) |
| | 2022 | 2022 | QUELLTX, INC. | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4345 | MIDDLESEX | USA | R44CA247110 | Development of anti-sense oligonucleotides as a therapeutic for cancer pain through selective block of sodium channel pain targets | 001 | 3 | NIH | 5/26/2022 | $995,305 |
| | 2022 | 2021 | QUELLTX, INC. | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4345 | MIDDLESEX | USA | R44AR074820 | A phenotypic screen for osteoarthritic pain therapeutics using all-optical electrophysiology. | 001 | 3 | NIH | 8/18/2022 | $0 |
| | 2022 | 2020 | QUELLTX, INC. | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4345 | MIDDLESEX | USA | R44CA247110 | Development of anti-sense oligonucleotides as a therapeutic for cancer pain through selective block of sodium channel pain targets | 000 | 1 | NIH | 5/13/2022 | $0 |
| | 2022 | 2019 | QUELLTX, INC. | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4345 | MIDDLESEX | USA | R44AR074820 | A phenotypic screen for osteoarthritic pain therapeutics using all-optical electrophysiology. | 000 | 1 | NIH | 6/8/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $1,696,519 ) |
| | 2021 | 2021 | QUELLTX, INC. | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4345 | MIDDLESEX | USA | R44AR074820 | A phenotypic screen for osteoarthritic pain therapeutics using all-optical electrophysiology. | 000 | 3 | NIH | 9/6/2021 | $696,518 |
| | 2021 | 2021 | QUELLTX, INC. | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4345 | MIDDLESEX | USA | R44CA247110 | Development of anti-sense oligonucleotides as a therapeutic for cancer pain through selective block of sodium channel pain targets | 001 | 2 | NIH | 5/25/2021 | $1,000,001 |
| | 2021 | 2020 | QUELLTX, INC. | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4345 | MIDDLESEX | USA | R44CA247110 | Development of anti-sense oligonucleotides as a therapeutic for cancer pain through selective block of sodium channel pain targets | 000 | 1 | NIH | 4/28/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,193,538 ) |
| | 2020 | 2020 | QUELLTX, INC. | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4345 | MIDDLESEX | USA | R44AR074820 | A phenotypic screen for osteoarthritic pain therapeutics using all-optical electrophysiology. | 001 | 2 | NIH | 8/24/2020 | $892,810 |
| | 2020 | 2020 | QUELLTX, INC. | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4345 | MIDDLESEX | USA | R44CA247110 | Development of anti-sense oligonucleotides as a therapeutic for cancer pain through selective block of sodium channel pain targets | 000 | 1 | NIH | 9/7/2020 | $300,728 |
| | 2020 | 2020 | QUELLTX, INC. | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4345 | MIDDLESEX | USA | R44AR074820 | A phenotypic screen for osteoarthritic pain therapeutics using all-optical electrophysiology. | 002 | 2 | NIH | 9/16/2020 | $0 |
| | 2020 | 2019 | QUELLTX, INC. | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4345 | MIDDLESEX | USA | R44AR074820 | A phenotypic screen for osteoarthritic pain therapeutics using all-optical electrophysiology. | 000 | 1 | NIH | 12/3/2019 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $230,695 ) |
| | 2019 | 2019 | QUELLTX, INC. | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4345 | MIDDLESEX | USA | R44AR074820 | A phenotypic screen for osteoarthritic pain therapeutics using all-optical electrophysiology. | 000 | 1 | NIH | 9/20/2019 | $230,695 |
|
|
